Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor

Wenxian Wang,1 Xiaowen Jiang,1 Zhengbo Song,1,2 Yiping Zhang1,2 1Department of Chemotherapy, Zhejiang Cancer Hospital, 2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People’s Republic of China Abstract: Anaplastic lymphoma kinase (ALK) rearra...

Full description

Bibliographic Details
Main Authors: Wang WX, Jiang XW, Song ZB, Zhang YP
Format: Article
Language:English
Published: Dove Medical Press 2016-01-01
Series:OncoTargets and Therapy
Subjects:
lung cancer
non-small-cell lung cancer
EML4-ALK
Crizotinib
EGFR
Icotinib;
Online Access:https://www.dovepress.com/patients-harboring-egfr-mutation-after-primary-resistance-to-crizotini-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/patients-harboring-egfr-mutation-after-primary-resistance-to-crizotini-peer-reviewed-article-OTT

Similar Items